Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT) (TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced that it has commenced an underwritten public offering of its common shares. The offering is being conducted in the United States pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission and in Canada pursuant to a final short form base shelf prospectus filed with the securities regulatory authorities in the Provinces of Québec, Ontario, Manitoba, Alberta and British Columbia. The number of common shares to be issued and the price of each common share will be determined at the time of pricing of the offering.
Investors are advised to consider carefully the business and risks of the Company before investing.
Roth Capital Partners and Euro Pacific Canada Inc. will act as joint book-running managers and National Securities Corporation, a wholly-owned subsidiary of National Holdings Inc. (NHLD), will act as lead manager for the offering. The Company expects to grant the underwriters participating in the offering a 30-day option to purchase up to an additional 15 percent of the number of common shares sold pursuant to the offering to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.